Research
Why Not Sirolimus for Active Lupus?
The Brief
- A trial from China tested a daily oral dose of sirolimus in patients with systemic lupus erythematosus (SLE) whose disease was uncontrolled despite standard therapy.
- Patients did well on the treatment, according to the trial as reported by MedPage Today from the ACR meeting in Orlando.
- Safety concerns were not entirely resolved by the results.
Why it matters
Sirolimus is an existing immunosuppressant, so a positive signal in refractory lupus could inform future treatment options for patients who are not controlled on standard therapy, though the safety questions need further evaluation.
Who’s affected
- rheumatologists and clinicians treating systemic lupus erythematosus
- patients with uncontrolled lupus
- #lupus
- #sirolimus
- #clinical trial
- #autoimmune disease
- #immunosuppression
(MedPage Today) -- ORLANDO -- Patients with systemic lupus erythematosus (SLE) that is uncontrolled despite standard therapy did well with a daily oral dose of sirolimus in a trial from China, although safety concerns weren't entirely relieved...